OREXO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.46 SEK | -0.48% |
|
+4.31% | +6.47% |
| Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
| Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Presentation Operator MessageOperator (Operator)Welcome to Orexo Q2 Report 2023. [Operator Ins...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.47% | 51.97M | |
| +4.06% | 70.44B | |
| +10.97% | 8.94B | |
| -14.44% | 4.75B | |
| +41.60% | 4.5B | |
| +5.96% | 3.85B | |
| +23.46% | 2.38B | |
| -19.32% | 2.34B | |
| -27.04% | 2.2B | |
| +7.97% | 1.96B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Transcript : Orexo AB, Q2 2023 Earnings Call, Jul 18, 2023
